ANAB ANAPTYSBIO, INC

8-K Current Report

Filed: March 3, 2026

Health Care

Pharmaceutical Preparations

ANAPTYSBIO, INC (ANAB) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 financial results announced March 3, 2026
• Detailed figures in Exhibit 99.1 press release — key metrics not disclosed in this filing item

Item 7.01 · Regulation FD Disclosure

• Reg FD disclosure: AnaptysBio releasing investor presentation (Exhibit 99.2) — signals potential pipeline, clinical, or strategic update material to valuation
• Full content in Exhibit 99.2; investors should review directly for pipeline timelines, data readouts, or partnering details

Get deeper insights on ANAPTYSBIO, INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.